Automatic antibody coupling and device for confirming same
The automated system for magnetic particle manufacturing and quality control addresses the inefficiencies of manual processes by using a cartridge with multiple wells and a magnetic rod, enabling consistent production and immunodiagnosis, enhancing efficiency and accessibility.
Patent Information
- Application Number
- PCT/KR2024/006722
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Conventional immunodiagnostic technologies using magnetic particles face challenges in manufacturing and quality control, particularly in producing consistent yields due to manual processes, which are skill-dependent and inefficient for large-scale production, and are limited in performing quantitative analysis due to the small size and floatation of silica-modified magnetic particles.
An automated system for manufacturing and quality control of magnetic particles, featuring a cartridge with multiple wells and a magnetic rod for antibody coupling and confirmation, allowing for simultaneous or sequential processing, enabling unskilled personnel to produce consistent magnetic particles and perform immunodiagnosis independently.
The system enables efficient, cost-effective, and reproducible manufacturing and quality control of magnetic particles, allowing for reliable immunodiagnosis, even in small quantities, with reduced time and skill requirements, and supports miniaturized, on-site diagnostic capabilities.
Smart Images

Figure PCTKR2024006722-APPB-IMG-000001 
Figure 00000026_0000 
Figure 00000027_0000
Abstract
Description
Automatic antibody coupling and a device for identifying it
[0001] The present invention relates to automatic antibody coupling and a device for confirming the same, and more particularly, to automatic antibody coupling and a device for confirming the same, which can automatically perform the manufacture of magnetic particles used for multiple diagnosis, and can simultaneously or sequentially perform quality control of the magnetic particles and diagnosis using the magnetic particles using the same system.
[0002] In vitro diagnostics (IVD) is a technology that analyzes substances collected from the human body, such as blood, urine, and cells, to diagnose health. It includes immunodiagnostics, self-blood glucose monitoring, and molecular diagnostics. Immunodiagnostics, based on detecting the presence of specific disease-causing proteins through antigen-antibody reactions, can be used to diagnose and track a wide variety of diseases. However, immunodiagnostics requires the target protein to be present at a concentration above the detection limit, which has led to the development of various technologies to amplify the signal generated by low-concentration proteins.
[0003] In particular, with the recent development of synthetic chemistry and life sciences, the target substances to be analyzed in fields such as new drug development and diagnosis have diversified, and various methods using magnetic particles have been reported as one of the detection methods that guarantee high-sensitivity signal generation to detect trace amounts of target substances. (Modern magnetic immunoassay: Biophysical and biochemical aspects (2017) Regul. Mech. Biosyst., 9(1), 47-55)
[0004] Conventional immunodiagnostics using magnetic particles have utilized nanometer-sized magnetic particles with silica-modified surfaces. However, these magnetic particles with silica-modified surfaces are difficult to effectively extract or release from the wells where the immune response is performed. Consequently, these small magnetic particles often float in solution, making separation difficult. Consequently, they are often used for qualitative rather than quantitative analysis. Furthermore, conventional analytical methods can only examine one magnetic particle at a time, making testing time-consuming and complex.
[0005] Meanwhile, the magnetic particles described above are used by attaching various antibodies, proteins, or nucleic acids to their surfaces. These antibodies, proteins, or nucleic acids can selectively bind to the organism of interest, enabling immunological diagnosis and other diagnostics.
[0006] However, in the case of existing immunodiagnostic technology, diagnosis and interpretation are automated, but in the case of manufacturing and quality inspection of magnetic particles, when manufacturing small quantities, researchers manufacture them directly, and even when manufacturing large quantities, workers or researchers manually control each step.
[0007] In the case of this type of manual control, the yield of the desired magnetic particles may vary depending on the skill level of the worker or researcher, and since highly skilled workers and researchers cannot be deployed to each use site, there is a disadvantage in that the desired magnetic particles cannot be supplied at the desired time.
[0008] Recently, as the use of magnetic particles has increased in various fields, there is a need for various types of magnetic particles. However, if such a manual manufacturing system is used, production according to demand cannot be performed, and in the case of inspections that use only a small amount of magnetic particles, it may be difficult to secure magnetic particles at the desired time.
[0009] Therefore, a new type of magnetic particle manufacturing system is needed to solve these problems.
[0010] In order to solve the above-mentioned problem, the present invention aims to provide an automatic antibody coupling and a device for confirming the same, which can automatically perform the manufacturing of magnetic particles used for multiple diagnosis, and can simultaneously or sequentially perform quality control of the magnetic particles and diagnosis using the magnetic particles using the same system.
[0011] In order to solve the above-described problem, the present invention provides an automatic antibody coupling and a device for confirming the same, comprising: a cartridge including a plurality of wells; a magnetic rod installed on the upper part of the wells of the cartridge and moving up and down to enter the inside of the wells; and an image acquisition unit capable of photographing the inside of at least one of the wells, wherein the cartridge is selectively used as at least one of a cartridge for automatic antibody coupling and a cartridge for confirmation after antibody coupling, and magnetic particles are loaded in at least one well of the cartridge.
[0012] In one embodiment, the magnetic particle comprises a core comprising a magneto-responsive metal; a shell layer surrounding the core and having a uniform thickness; and a capture probe introduced onto the shell layer for capturing a biological material, wherein the magnetic particle may be a cut piece of a glass-coated metal microwire.
[0013] In one embodiment, the automatic antibody coupling and the device for confirming the same may further include a tip cover that surrounds the lower portion of the magnetic bar and moves up and down simultaneously with or separately from the magnetic bar.
[0014] In one embodiment, the cartridge for automatic antibody coupling may include a first well loaded with the magnetic particles; a second well loaded with EDC and NHS; a third well loaded with a capture antibody; a fourth well containing a blocking buffer; and a fifth well containing a washing buffer.
[0015] In one embodiment, the first well and the second well may additionally include a 2-[N-morpholino]ethanesulfonic acid (MES) buffer.
[0016] In one embodiment, a buffer buffer well is additionally included between the fourth well and the fifth well, and the third well and the buffer buffer well may include a 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES) buffer.
[0017] In one embodiment, the confirmation cartridge after antibody coupling may include a first well loaded with magnetic particles coupled to the capture antibody; a second well loaded with a second agent; a third well loaded with fluorescent particles; and a fourth well containing a washing buffer.
[0018] In one embodiment, the second antibody binds to the capture antibody through an antigen-antibody reaction, and the fluorescent particle can bind to the second antibody.
[0019] In one embodiment, the first to third wells may additionally include a blocking buffer.
[0020] In one embodiment, the cartridge may further comprise an immunodiagnostic cartridge.
[0021] In one embodiment, the immunodiagnostic cartridge may include a first well loaded with magnetic particles coupled with capture antibodies; a second well loaded with antigens; a third well loaded with detection antibodies; a fourth well loaded with fluorescent particles; and a fifth well containing a washing buffer.
[0022] In one embodiment, the magnetic particles coupled with the capture antibodies are a mixture of two or more magnetic particles having different lengths, and the magnetic particles having different lengths may include different capture antibodies.
[0023] In one embodiment, the automatic antibody coupling and the device for confirming the same can perform the coupling process of the magnetic particles and the confirmation process of the coupled magnetic particles by moving the magnetic bar vertically and horizontally.
[0024] The automatic antibody coupling and the device for confirming the same according to the present invention can perform manufacturing and quality control of magnetic particles simultaneously or sequentially within the same system, so that manufacturing and quality control of magnetic particles can be performed using a single system.
[0025] In addition, the automatic antibody coupling and the device for confirming the same according to the present invention enable even unskilled personnel to manufacture magnetic particles in the same manner as skilled personnel, so diagnosis can be made at a lower cost than conventional immunodiagnosis.
[0026] In addition, the automatic antibody coupling and the device for confirming the same according to the present invention can perform not only the manufacturing and quality inspection of magnetic particles but also immunodiagnosis within the same system, so that immunodiagnosis can be performed independently even with minimal eye power and equipment.
[0027] Figure 1 is a schematic diagram of four important technologies used in an automatic antibody coupling and a device for confirming the same according to one embodiment of the present invention.
[0028] Figure 2 illustrates an automatic antibody coupling according to one embodiment of the present invention, a device for confirming the same, and a cartridge used therefor.
[0029] Figure 3 illustrates a method for manufacturing magnetic particles according to one embodiment of the present invention.
[0030] Figure 4 is a microscopic image of the diameter, length, etc. of magnetic particles according to one embodiment of the present invention.
[0031] Figure 5 illustrates a chemical surface treatment process of magnetic particles according to one embodiment of the present invention.
[0032] FIG. 6 illustrates an example of a length coding system of a magnetic microrod performing a multi-detection function according to one embodiment of the present invention.
[0033] Figure 7 shows a flow chart of automatic antibody coupling according to one embodiment of the present invention.
[0034] Figure 8 illustrates the configuration of a cartridge for automatic antibody coupling according to one embodiment of the present invention.
[0035] Figure 9 illustrates a confirmation process after antibody coupling according to one embodiment of the present invention.
[0036] Figure 10 shows the configuration of a confirmation cartridge after antibody coupling according to one embodiment of the present invention.
[0037] Figure 11 illustrates an immune diagnosis process according to one embodiment of the present invention.
[0038] Figure 12 illustrates the configuration of an immune diagnosis cartridge according to one embodiment of the present invention.
[0039] Hereinafter, preferred embodiments of the present invention will be described in detail. In describing the present invention, if a detailed description of related known technology is judged to obscure the gist of the present invention, the detailed description will be omitted. Throughout the specification, singular expressions should be understood to include plural expressions unless the context clearly indicates otherwise, and terms such as “comprise” or “have” should be understood to indicate the presence of described features, numbers, steps, operations, components, parts, or combinations thereof, but do not preemptively exclude the possibility of the presence or addition of one or more other features, numbers, steps, operations, components, parts, or combinations thereof. In addition, when performing a method or a manufacturing method, each step constituting the method may occur in a different order from the stated order, unless the context clearly indicates a specific order. That is, each step may occur in the same order as the stated order, may be performed substantially simultaneously, or may be performed in the opposite order.
[0040] The technology disclosed in this specification is not limited to the implementation examples described herein and may be embodied in other forms. However, the implementation examples introduced herein are provided to ensure that the disclosed content is thorough and complete and to ensure that the technical spirit of the present technology can be sufficiently conveyed to those skilled in the art. In the drawings, the dimensions of each device component, such as width and thickness, are somewhat enlarged to clearly represent the components. The drawings are described from the perspective of an observer, and when an element is mentioned as being positioned above another element, this includes the meaning that the element is positioned directly above the other element or that additional elements may be interposed between them. Furthermore, those skilled in the art will be able to implement the spirit of the present invention in various other forms without departing from the technical spirit of the present invention. In addition, the same reference numerals in multiple drawings indicate substantially the same elements.
[0041] As used herein, the term "and / or" includes a combination of multiple listed items or any one of multiple listed items. As used herein, "A or B" can include "A," "B," or "both A and B."
[0042] The present invention relates to an automatic antibody coupling and a device for confirming the same, comprising: a cartridge including a plurality of wells; a magnetic rod installed on the upper part of the wells of the cartridge and moving up and down to enter the inside of the wells; and an image acquisition unit capable of photographing the inside of at least one of the wells, wherein the cartridge is selectively used as at least one of a cartridge for automatic antibody coupling and a cartridge for confirmation after antibody coupling, and magnetic particles are loaded in at least one well of the cartridge.
[0043]
[0044] The above well refers to a space loaded with magnetic particles, buffers, antibodies, etc., and may have a size that allows a magnetic bar, which will be described later, to enter from the top. In addition, the cartridge may have a shape in which the above wells are arranged in a single row, and such a cartridge may have a sealed top so as to be isolated from the outside until use. In addition, the cartridge may be composed of a single row of wells as described above, but it may also be manufactured in a form that is connected to the side of each cartridge so that the wells have a grid-like arrangement (see Fig. 2).
[0045] The magnetic particles may be loaded into one or more of the above wells. In the present invention, they may preferably be loaded into the first well.
[0046] The magnetic particle comprises a core including a magneto-responsive metal; a shell layer surrounding the core and having a uniform thickness; and a capture probe introduced onto the shell layer to capture a biological material, wherein the magnetic particle may be a cut piece of a glass-coated metal microwire (see FIGS. 3 and 4).
[0047] The core may include a magneto-responsive metal, preferably a magnetic metal or a metal alloyed with a magnetic metal. The magnetic metal may be an alloy containing iron (Fe), nickel (Ni), cobalt (Co), or manganese (Mn). The magneto-responsive metal may include a transition metal such as iron, nickel, cobalt, or manganese as a main component, and a rare earth metal such as gadolinium (Gd), terbium (Tb), or samarium (Sm), and may also include boron (B), silicon (Si), or carbon (C). Representative examples of the magneto-responsive metal include an iron alloy or a cobalt alloy. A specific example of an iron alloy may be Fe70B15Si10C5, and an example of a cobalt alloy may be Co68Mn7Si10B15. In addition, the magnetic metal may be mixed or alloyed with copper (Cu), gold (Au), silver (Ag), iron (Fe), or platinum (Pt), and more preferably, may include a superparamagnetic metal. Although the core does not directly have magnetism, it may be magnetized as a magnet approaches and have an attractive force with the magnet, and thus may be usefully used for movement and mixing using a magnet. However, in the case of the present invention, it is preferable to use a paramagnetic material rather than a ferromagnetic material. This is to reduce the formation of agglomerations due to the magnetic attraction between each magnetic particle when the magnet is removed. However, when a ferromagnetic material is used, individual fluorescence observation of each particle may not be easy due to this agglomeration phenomenon. Therefore, the core of the present invention preferably uses ferromagnetic particles. In addition, it is preferable that the magnetic particles have a size and specific gravity that do not float in water so that they can be quickly collected or separated by an external magnet such as a permanent magnet or an electromagnet.
[0048] The core may occupy 60% or more of the total volume of the magnetic particles. For example, the core may be 60 to 99%, preferably 75 to 99%, of the total volume of the magnetic particles. In addition, the magnetic particles may have a size (e.g., diameter or length) of several tens to several hundred micrometers, and a specific gravity of 5 or more, for example, preferably 5 to 30. If the magnetic particles are nanoparticles having a size of less than 1 micrometer, even if the particles have a high specific gravity (e.g., 7.876 for iron), they may float in water. In this case, in the bioassay process of detecting biological substances in a well using magnetic particles, when a magnetic field is applied, the magnetic control of the magnetic particles may not be smooth due to the low magnetic force of the fine particles, which may cause difficulties in separation. When the magnetic rod is moved up and down within the well to stimulate an immune response, the attachment and detachment of microparticles occur. However, due to their low weight, magnetic particles that have once attached to the rod during this movement may not fall back to the bottom of the well even after the magnetic field is removed, but instead remain nonspecifically bound to the rod. This can reduce the reproducibility of quantitative analysis when detecting biological substances within the well.
[0049] Meanwhile, the magnetic particles have a core-shell structure by having a magnetically responsive metal at the center and a shell layer surrounding the center. The shell layer may be made of an organic or inorganic material, and is preferably glass.
[0050] The above glass may be composed primarily of a compound selected from the group consisting of soda lime, borosilicate, aluminosilicate, silica, alkali silicate, Pyrex, and quartz. Preferably, it is for experimental use requiring heat resistance, acid resistance, and water resistance, and may be borosilicate, which can minimize nonspecific binding to antibodies.
[0051] The above shell surface may include a hydrophilic functional group.
[0052] In the case of the above shell surface, it can be combined with a capture probe to be described later, including various functional groups, wherein the functional group is a hydrophilic functional group, and the hydrophilic functional group can be a silanol group or a carboxyl group, amino group, hydroxyl group, thiol group, or aldehyde group derived from a silanol group. More preferably, the functional group can be a silanol group.
[0053] In addition, the hydrophilic functional group may be directly bonded to the capture probe, but preferably, it may be bonded using a linker. The linker is positioned between the hydrophilic functional group and the capture probe to facilitate attachment of the capture probe to the shell layer. Preferably, a silane compound, more preferably an amino-silane, and most preferably 3-aminopropyltrimethoxysilane (APTES) may be used.
[0054] The above silane compound may preferably have a structure of H2N-L-Si(OR)3. In this case, L is a C1 to C12 alkylene or a C6 to C20 arylene, or an alkylene and an arylene are optionally combined. In addition, a part of the main chain of L may be substituted with 0 to 4 -NH-, and R is hydrogen or a C1 to C8 alkyl (see FIG. 5).
[0055] The above silane compound may preferably be an amino-silane, and specific examples of the amino-silane include 3-aminopropyltriethoxysilane, aminosilane hydrolysate, 3-aminopropyltrimethoxysilane, 2-aminoethyl-3-aminopropyltrimethoxysilane, 2-aminoethyl-3-aminopropyltriethoxysilane, 2-aminoethyl-3-aminopropylmethyldimethoxysilane, 3-aminopropylmethyldiethoxysilane, It may be at least one selected from the group consisting of 3-aminopropyltrimethoxysilane, N-2-aminoethyl-3-aminopropyltriethoxysilane, trimethoxysilylpropyldiethylenetriamine, bis(trimethoxysilypropyl)amine, and bis(triethoxysilypropyl)amine. Preferably, 3-aminopropyltrimethoxysilane (APTES) may be used considering cost efficiency. In one embodiment, the amine terminal may be substituted with a carboxyl group so that it can be easily combined with the capture probe.
[0056] Additionally, the shell layer may substantially completely surround the magnetic particle, but if necessary or during the manufacturing process, the surface of the fine particle may not be completely covered by the shell layer and some areas of the surface of the magnetic particle may be exposed.
[0057] In order to capture the biological material in the sample solution, a magnetic particle according to one embodiment of the present invention may have a capture probe introduced on the shell layer. The capture probe specifically binds to an antibody, which will be described later, and captures the antibody to the magnetic particle. The capture probe may be fixed by adsorbing it to the surface of the magnetic particle or by chemically linking it, and preferably may be linked to a hydrophilic functional group present on the surface of the shell layer. For example, biotin may be introduced to the surface of the capture probe, and avidin, neutravidin, or strepavidin, which bind to biotin, may be introduced to the magnetic particle to attach the capture probe to the magnetic particle. At this time, the capture probe may be linked to the magnetic particle using the hydrophilic functional group on the surface of the magnetic particle.
[0058] At this time, the hydrophilic functional group may be directly bonded to the capture probe, but may preferably be bonded using a linker. The linker may be a silane compound.
[0059] The above core-shell structure may be formed by applying a liquid shell component to a core metal or by filling a core metal component into a hollow mold.
[0060] The shell layer may be solidified from a liquid coating solution of an organic or inorganic substance. More specifically, the shell layer may be formed by melting an organic or inorganic shell component at high temperature, making it flowable, or dissolving it in a solvent to prepare a liquid coating solution, and then applying the liquid coating solution to the core metal. The organic material may mainly be a polymer, and the inorganic material may be a metal or ceramic, particularly glass. For example, a coating solution obtained by dissolving plastic in a solvent or melting glass to form a shell layer may be applied to the magnetic particles by dip coating, spray coating, or the like.
[0061] The auto-antibody coupling cartridge may be loaded with magnetic particles of the same length. That is, in the case of the present invention, magnetic particles bound to the same antibody can be produced in a single auto-antibody coupling cartridge, and if magnetic particles bound to multiple antibodies are required, multiple auto-antibody coupling cartridges may be connected in parallel and used. Looking into this in detail, in the case of the auto-antibody coupling cartridge of the present invention, the magnetic particles are supplied with the magnetic particles loaded inside, and the auto-antibody coupling cartridge may be supplied in a sealed state to prevent contamination. In this case, when loading multiple antibodies, not only does the absolute amount of magnetic particles produced decrease, but also the sensitivity may be lowered or only some antibodies may have increased sensitivity due to competition between each antibody. In addition, when loading multiple antibodies, multiple antibodies may bind to magnetic particles of the same length, making it impossible to perform multiple detection according to length. Therefore, in the case of the present invention, it is preferable that the auto-antibody coupling cartridge loads magnetic particles of the same length, and that only one antibody is coupled.
[0062] The above magnetic particles may be cut pieces of glass-coated metal microwires. Magnetic particles of various lengths can be easily obtained by simply cutting the glass-coated metal microwires with a laser.
[0063] The magnetic particles may have various shapes, including regular shapes such as rods, flat plates, and spheres, or irregular shapes. Even when the magnetic particles have a flat plate shape, the cross-section may have various shapes such as stars, polygons, and circles, and is not particularly limited. Preferably, the magnetic particles are in the shape of microrods, microdiscs, or microbeads for ease of manufacture and observation, and are particularly preferred in the shape of microrods. When the magnetic particles have the shape of microrods, it is easy to distinguish between the magnetic particles due to their overlap, and when placed within a well, focusing is easy, and since the area occupied by each particle is small, a large number of fine particles can be observed on a single observation screen. On the other hand, when the magnetic particles have a shape with a complex cross-section, such as a star shape, the edges may break due to collisions with each other or the walls while moving within the well. Therefore, it is more advantageous to have a simple shape, such as a microrod.
[0064] The length of the microrods may be 10 to 1,000 μm. If the length of the microrods is less than the above range, it may not be easy to distinguish between particles of different lengths, and as the size of the particles decreases, the magnetism may decrease, making mixing, washing, and movement using a magnet difficult. In addition, if the length of the microrods exceeds the above range, the particles may overlap, making observation difficult, and it may be difficult to place the desired amount of magnetic particles in one well, making smooth diagnosis difficult. In addition, the ratio of the length to the diameter of the microrods (aspect ratio) may be 2 or more, 5 or more, or 10 or more, and the aspect ratio may preferably be 20 or less. If the aspect ratio is less than 2, it may be difficult to distinguish between spherical fine particles because they resemble each other, and if the aspect ratio exceeds 20, as the diameter of the magnetic particles decreases, the core portion having relative magnetism may become thinner, thereby weakening the magnetism. Additionally, when the aspect ratio exceeds 20, durability may be reduced due to the thin diameter, which may cause the magnetic particles to break during inspection.
[0065] The above cartridge may be selectively used as one or more of a cartridge for automatic antibody coupling and a cartridge for confirmation after antibody coupling.
[0066] Conventional antibody coupling methods are typically produced in laboratories. This labor-based manufacturing method offers the advantage of facilitating the production of small quantities of antibody-coupled particles. In particular, for antibody-based diagnostic methods like the present invention, multiple types of particles are required, and each antibody must be coupled. Therefore, labor-based manufacturing methods, which are suitable for small-scale production, are widely used.
[0067] However, in the case of these human-based manufacturing methods, the yield of coupled particles can vary significantly depending on the manufacturer's skill level. Furthermore, false negatives frequently occur when particles with low yields are used, making it crucial to retain skilled personnel. Furthermore, even when manufactured by skilled personnel, the nature of human-based manufacturing methods often means that different amounts of reagents are used for each manufacturing run, resulting in inconsistent yields.
[0068] In the case of the present invention, by using the cartridge and automatic antibody coupling device as described above, it is possible to provide coupled particles having a constant yield and a higher yield than a manpower-based manufacturing method.
[0069] Furthermore, in the case of existing automated coupling devices, the post-coupling verification process (QC) is typically performed by personnel or using a different type of verification device. However, in the case of the present invention, as described above, the same device is used, but a post-antibody coupling verification cartridge is used, allowing for easy verification of the manufactured magnetic particles using the same device.
[0070] The above-described cartridge for auto-antibody coupling may include a first well loaded with the magnetic particles; a second well loaded with EDC and NHS; a third well loaded with a capture antibody; a fourth well containing a blocking buffer; and a fifth well containing a washing buffer (see FIG. 7).
[0071] Since the magnetic particles are as described above, their description will be omitted.
[0072] The magnetic particles may sequentially move from the first well to the fifth well, and coupling may be performed. At this time, the movement of the magnetic particles and mixing within the wells are performed using a magnetic bar, which will be described later.
[0073] The configuration of the cartridge for auto-antibody coupling is explained through the auto-antibody coupling method using the cartridge for auto-antibody coupling (see Fig. 7).
[0074] First, the magnetic particles loaded in the first well can be moved to the second well. The first well may be loaded with the magnetic particles, and a 2-[N-morpholino]ethanesulfonic acid (MES) buffer may be additionally injected. Through this, the magnetic particles of the present invention can be stored for a long period of time, and can be stored in a state where they can float within the first well without additional buffer injection during use.
[0075] The magnetic particles moved to the second well can react with EDC and NHS.
[0076] In the present invention, the EDC refers to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, which is used to generate an amide bond. Looking at this in detail, the EDC can be used as a carboxyl activator for coupling primary amines.
[0077] In addition, the above NHS stands for N-Hydroxysuccinimide and is used simultaneously with the above EDC to bind NH2 to an antibody.
[0078] When using the above EDC and NHS, NH2 can be combined with the carboxyl group (-COOH) present in the magnetic particles, and the mechanism for this is as shown in the following reaction scheme 1.
[0079] [Reaction Formula 1]
[0080]
[0081] Additionally, the second well may be injected with MES buffer to increase the reaction buffer. In the case of the EDC, the reaction can be performed at a low pH. Therefore, by using the MES buffer as described above, these pH conditions can be satisfied.
[0082] When the reaction is completed in the second well as described above, the magnetic particles can be moved to the third well. The third well is loaded with a capture antibody, and the capture antibody can be bound to a capture probe present on the surface of the magnetic particles. In addition, when the cartridge for auto-antibody coupling includes each capture probe, the capture antibody can also be present in the same quantity as each cartridge, thereby producing a magnetic particle capable of detecting multiple antigens simultaneously. The third well may additionally include a 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES) buffer. The HEPES buffer is a type of buffer that can buffer the production of carbon dioxide and can also be used to control reaction conditions.
[0083] The magnetic particles bound to the capture antibody in the third well can be moved to the fourth well. The fourth well is loaded with a blocking buffer, and the blocking buffer can bind to the portion of the surface of the magnetic particles to which the capture antibody is not bound. This can prevent nonspecific binding of antigens or fluorescent substances to the capture antibody, thereby reducing false positives and simultaneously increasing sensitivity.
[0084] As described above, the magnetic particles combined with the blocking buffer can be moved to the fifth well and washed. The fifth well is loaded with a washing buffer, and by washing in the fifth well, excess antibodies, buffers, etc. can be removed. In addition, the fifth well may be a single well, but may also be composed of 2 to 5 wells, and by washing sequentially in these wells, the washing effect can be increased.
[0085] A buffer buffer well may be additionally included between the fourth and fifth wells. In the fourth well, binding with the blocking buffer as described above may be performed, and during this process, the pH or carbon dioxide concentration may change. Therefore, to reduce such changes, it is preferable to add a buffer buffer well loaded with a buffer buffer between the fourth and fifth wells. The buffer buffer used at this time may be any buffer capable of buffering changes in pH or carbon dioxide concentration, but it is preferable to use a HEPES buffer.
[0086] As described above, the magnetic particles that have been washed can be stored in a blocking buffer. In addition, a storage well containing a blocking buffer can be installed at the rear end of the fifth well, i.e., the last well of the cartridge, to load the blocking buffer and store the manufactured magnetic particles.
[0087] As described above, the magnetic particles of the present invention can undergo antibody coupling by starting from the first well and reaching the fifth well. However, these magnetic particles that have undergone antibody coupling cannot be used as is, and it is preferable to go through a verification process to ensure that coupling has been completed accurately.
[0088] In addition, the first to fifth wells may be arranged sequentially as described above, but each well may have a different arrangement depending on the reaction conditions within the well. For example, if heating is required for the reaction within the first well and the reaction within the third well, the heating efficiency can be increased by arranging them in the order of the first well, third well, and second well instead of the order of the first well, second well, and third well, and the side reaction of the second well, which does not require heating, can be reduced.
[0089] In addition, unused wells may exist between the above-mentioned wells. In general, standardized cartridges are used for the auto-antibody coupling and post-coupling confirmation cartridges. That is, it is preferable to use cartridges having the same wells for the auto-antibody coupling and post-coupling confirmation cartridges. In addition, it is preferable that the magnetic particles for which coupling and confirmation have been completed are stored in the last well of the cartridge. In this case, if the number of wells required is less than the number of wells existing in the cartridge, it is preferable to place the unused wells in the middle of the cartridge so that the magnetic particles for which coupling and confirmation have been completed are present in the last well. In addition, these unused wells can be used to secure a space between each well, which can minimize side reactions in the main well when the internal conditions of the well are changed due to heating, etc., as described above.
[0090] The well configuration of these cartridges applies equally not only to the above-described autoantibody coupling cartridges but also to the antibody coupling post-confirmation cartridges and immunodiagnostic cartridges described below.
[0091] As discussed above, in the case of the existing verification (QC) process, it is common to perform it based on manpower or use separate equipment, but in the case of the present invention, it is possible to perform the verification process using the same equipment by exchanging the cartridge for automatic antibody coupling with a cartridge for confirmation after antibody coupling.
[0092] The above-described post-antibody coupling confirmation cartridge may include a first well loaded with magnetic particles coupled with capture antibodies; a second well loaded with a second agent; a third well loaded with fluorescent particles; and a fourth well containing a washing buffer (see FIG. 10).
[0093] The configuration of the cartridge for confirmation after the above antibody coupling will also be described according to the confirmation method after the antibody coupling (see Figure 9).
[0094] The first well may be loaded with magnetic particles coupled with capture antibodies. At this time, the magnetic particles coupled with the capture antibodies are preferably magnetic particles manufactured in the auto-antibody coupling cartridge, but it is also possible to load and use magnetic particles manufactured using other methods. In addition, the post-antibody coupling confirmation cartridge may not separately load magnetic particles, and in this case, it may be configured in parallel with the auto-antibody coupling cartridge so that the magnetic particles manufactured in the auto-antibody coupling cartridge can be directly transferred to the first well for use. In addition, when a plurality of auto-antibody coupling cartridges are arranged and used, the post-antibody coupling confirmation cartridge may be positioned in the last row of the auto-antibody coupling cartridges so that some of the magnetic particles manufactured in the auto-antibody coupling cartridges can be confirmed.
[0095] As described above, the magnetic particles loaded in the first well can be moved to the second well. The second well is loaded with a second antibody, and the second antibody can bind to the capture antibody through an antigen-antibody reaction. That is, after the antibody coupling, the capture antibody can act as an antigen for the second antibody in the confirmation cartridge. By using the second antibody as described above, it is possible to confirm whether the capture antibody is normally bound, and since the capture antibody does not bind to the fluorescent particle described below, fluorescence detection can be performed using the second antibody.
[0096] As described above, the magnetic particles bound to the second antibody can be moved to the third well. The third well is loaded with fluorescent particles, and the fluorescent particles can bind to the second antibody. That is, by binding the second antibody and the fluorescent particles, it can be confirmed that the capture antibody is accurately bound, and by measuring the intensity of fluorescence generated by the fluorescent particles, it is also possible to confirm the binding density of the capture antibody.
[0097] The fluorescent particle can be linked to the second antibody to generate light by external stimulation such as ultraviolet rays, electron beams, chemical reactions, enzyme-substrate reactions, etc. Examples of the luminescent material include fluorescent molecules, quantum dots, metal nanoparticles, magnetic nanoparticles, enzymes, enzyme substrates, etc. Among these, in terms of availability and convenience of application, a fluorescent molecule selected from the group consisting of FITC (fluorescein isothiocyanate), fluorescein, FAM (fluorescein amidite), PE (phycoerythrin), TRITC (tetramethyl-rhodamine isothiocyanate), Cy3 (Cyanine 3), Cy5 (Cyanine 5), Cy7 (Cyanine 7), Alexa fluorine dyes, and rhodamine can be commonly used as the luminescent material.
[0098] The first to third wells may contain a blocking buffer. The blocking buffer may prevent non-specific binding by binding to a portion of the surface of the magnetic particle to which the detection probe is not bound. Since the surface of the magnetic particle is made of glass, non-specific binding may occur. This non-specific binding means that an antigen, a second antibody, a detection antibody, or a fluorescent particle binds to a portion other than the detection probe, and in the case of such non-specific binding, it has the side effect of showing a false positive or increasing the detection limit. Therefore, by using the blocking buffer as described above, it is possible to prevent non-specific binding to the surface of the magnetic particle to which the capture probe is not bound.
[0099] As described above, the magnetic particles bound to the fluorescent particles can be moved to the fourth well and washed. The fourth well is a well loaded with a washing buffer for washing the magnetic particles, and may be composed of a single well, similar to the fifth well of the auto-antibody coupling cartridge, or may be composed of multiple wells. In the fourth well, the second antibody and fluorescent particles that are not bound to the capture antibody can be removed.
[0100] As described above, after washing is completed, the magnetic particles can be identified by supplying fluorescence. In the case of magnetic particles to which the capture antibody is normally bound, as described above, fluorescence can be generated by the fluorescent particles. In addition, when a smaller number of capture antibodies are used than the types of magnetic particles, it can be confirmed whether the desired type of capture antibody is bound by confirming that the magnetic particles of the desired length emit light. In addition, by observing the intensity of fluorescence emitted by the magnetic particles, the binding density of the capture antibody can be confirmed, and through this, it can be confirmed whether the antibody coupling is accurate.
[0101] In addition to the above-described autoantibody coupling and identification device, the present invention can also be used for immunodiagnosis. The post-antibody coupling identification method is performed using a process nearly identical to immunodiagnosis, meaning that immunodiagnosis can be performed by replacing some reagents and adding antigens. In other words, the present invention's autoantibody coupling and identification device can be used for not only antibody coupling and identification of coupled magnetic particles, but also immunodiagnosis, all under the same process (see Fig. 11).
[0102] In addition, the cartridge for immune diagnosis, similar to the cartridge for confirmation after antibody coupling, may also be used by exchanging it after using the cartridge for automatic antibody coupling and the cartridge for confirmation after antibody coupling, or may be connected in parallel with the cartridge for automatic antibody coupling and the cartridge for immune diagnosis to move the magnetic particles produced in the cartridge for automatic antibody coupling to the first well.
[0103] In this case, when the type of magnetic particles required for the above-mentioned immunodiagnostic cartridge is n, n+m cartridges for the auto-antibody coupling can be used, and it is preferable that m cartridges for confirmation after the antibody coupling are used. When used in this ratio, coupling of the desired type and number of magnetic particles is possible in the auto-antibody coupling cartridge, and among these, the amount of m cartridges is confirmed in the confirmation cartridge after the antibody coupling, and the remainder can be transferred to the immunodiagnostic cartridge and used (see Fig. 2).
[0104] The above-mentioned immunodiagnostic cartridge may include a first well loaded with magnetic particles coupled with capture antibodies; a second well loaded with antigens; a third well loaded with detection antibodies; a fourth well loaded with fluorescent particles; and a fifth well containing a washing buffer (see Article 12).
[0105] The first well may be loaded with magnetic particles coupled with capture antibodies. While the magnetic particles may be manufactured through another process, they may preferably be magnetic particles manufactured in the auto-antibody coupling cartridge and then transferred. As described above, in the present invention, since coupling is performed automatically through the auto-antibody coupling cartridge, the magnetic particles manufactured in the auto-antibody coupling cartridge can be used. Furthermore, since the same process and device are used, miniaturization of the device and uniform analysis can be achieved.
[0106] The magnetic particles coupled with the capture antibodies are a mixture of two or more magnetic particles having different lengths, and the magnetic particles having different lengths may contain different capture antibodies (see Fig. 6). By using this, fluorescence of different lengths is generated depending on each capture antibody, so that two or more biomarkers can be diagnosed simultaneously. To this end, the magnetic particles coupled with the capture antibodies can be used by mixing 2 to 20 types of magnetic particles coupled with capture antibodies having a length difference of 5 to 200 μm. By using magnetic particles coupled with capture antibodies of various lengths, 2 to 20 types of biomarkers can be detected simultaneously. At this time, if the length difference between the magnetic particles coupled with the respective capture antibodies is less than 5 μm, it is difficult to distinguish the length difference using optical equipment, and if it exceeds 200 μm, discrimination is easy, but it is difficult to use magnetic particles coupled with multiple capture antibodies, making it difficult to distinguish multiple biomarkers simultaneously.
[0107] For example, a capture antibody that performs an antibody-antigen reaction with GFAP can be bound to the surface of a magnetic particle having a length of 300 μm, and a capture antibody that performs an antibody-antigen reaction with UCHL-1 can be bound to the surface of a magnetic particle having a length of 400 μm. When the magnetic particles coupled with the two types of capture antibodies are mixed and used, the magnetic particles coupled with the capture antibodies generate the same fluorescence, but due to the difference in the length of the magnetic particles, it is possible to determine whether the biomarker is GFAP (fluorescence length 300 μm) or UCHL-1 (fluorescence length 400 μm). This means that the type of biomarker can be accurately determined simply through optical observation without using a genetic confirmation method such as PCR.
[0108] This expands to mean that by binding each capture antibody to 10 different magnetic particles of different lengths and mixing them, 10 different biomarkers can be identified simultaneously. However, if the number of magnetic particles of different lengths exceeds 20, the quantity of each magnetic particle may not be enough to exhibit appropriate fluorescence, and since a large amount of magnetic particles must be injected to exhibit sufficient fluorescence, the efficiency may be reduced.
[0109] In addition, as discussed above, in order to manufacture the above-described various magnetic particles, a cartridge for coupling multiple autoantibodies is required. In this case, the magnetic particles coupled with the capture antibodies loaded into the first well of the immunodiagnostic cartridge may be derived from multiple autoantibody coupling cartridges.
[0110] The second well above is loaded with an antigen. The antigen refers to a detection target substance contained in the sample, and an antigen-antibody reaction is performed with the antibody coupled to the magnetic particle of the present invention.
[0111] The antigen used at this time may be a pathogen, and the pathogen may include bacteria, spirochetes, rickettsiae, viruses, fungi, parasites, etc. In addition, the pathogen may be used as a biomarker (antigen) as it is, but tissue extracts, cell lysates, proteins, DNA, RNA, etc. of the pathogen may also be used as a biomarker (antigen). In addition, since the human body performs an antigen-antibody reaction when the pathogen invades, it is also possible to use antibodies against the pathogen as a biomarker.
[0112] In addition, in the case of the above antigen, not only antigens derived from microorganisms outside the human body as described above, but also biological substances existing inside the human body can be used as antigens. In this case, the biological substances may be biomarkers, blood, plasma, serum, body fluids, proteins, peptides, nucleic acids, bacteria, viruses, endoplasmic reticulum, miRNA, exosomes, circulating tumor cells, etc. Preferably, the biological substances may be biomarkers.
[0113] In particular, the technology disclosed herein can be very useful for biomarker detection, as it can detect multiple biological substances in a single test, enabling rapid and early diagnosis of diseases. The biomarkers may be used without limitation in any conventional scientific or medical field, such as measuring or evaluating biological processes, pathogenic processes, or pharmacological processes for treatment. The biomarkers may be, for example, polypeptides, peptides, nucleic acids, proteins, or metabolites detectable in biological fluids such as blood, saliva, or urine.
[0114] In addition, the above specimen may be a specific sample liquid derived from a living organism, and the sample liquid may be a tissue extract, cell lysate, whole blood, plasma, serum, saliva, ocular fluid, cerebrospinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid, etc. For rapid diagnosis, the preprocessing of the sample liquid may be simplified or, in some cases, omitted.
[0115] As described above, the antigen-bound magnetic particles can be moved to the third well. The third well is loaded with a detection antibody, and the detection antibody can bind to the antigen. At this time, the capture antibody and the detection antibody can bind to different parts of the antigen, and by binding to each location as described above, a decrease in analysis efficiency can be prevented.
[0116] The magnetic particles bound to the detection antibody in the third well can be moved to the fourth well. The fourth well is a well loaded with fluorescent particles, and the fluorescent particles can bind to the detection antibody. That is, in the case of the present invention, when the antigen is present, the detection antibody and fluorescent particles are sequentially bound to emit fluorescence, so that the type of antigen can be accurately identified. In addition, the fluorescent particles bind only to the detection antibody, and the blocking buffer prevents them from being adsorbed to other surfaces of the magnetic particles, so that even low concentrations of antigen can be detected.
[0117] Once the binding of the fluorescent particles is completed as described above, they can be washed in the fifth well. The fifth well is loaded with a washing buffer, and unbound antibodies and fluorescent particles can be removed. The fifth well may consist of a single well, but may also consist of two to five wells that can be washed sequentially.
[0118] Detection in the above fifth well can be performed using an immunodiagnostic method. In particular, detection of the luminescent signal can be performed using, for example, an ELISA method or a fluorescence measurement method.
[0119] To explain more specifically, the ELISA method binds the target substance in the sample to a capture antibody fixed to a giant magnetic particle, and then processes the detection antibody. This detection antibody binds to the opposite side of the target substance to which the capture antibody bound. The detection antibody is conjugated with an enzyme called horse radish peroxidase (HRP), which breaks down the TMB substrate using hydrogen peroxide to produce a color. The degree of this color is measured as the OD value. In other words, this method utilizes the principle that as the target substance in the sample increases, the capture and detection antibodies quantitatively increase in proportion, and as a result, the HRP conjugated to the detection antibody increases, so the enzymatic reaction proceeds relatively quickly, causing the color of the TMB substrate to change quickly. By pre-treating the target substance at various concentrations and drawing a standard curve using the OD values obtained, and then comparing the OD values obtained after treating the actual sample with the standard curve, the amount of the target substance in the sample can be measured. All OD value calculations and concentration calculations can be performed using the automatic analysis program installed on the analytical instrument.
[0120] The principle of the fluorescence measurement method is the same as the ELISA method, which uses a sandwich assay using a capture antibody and a detector antibody, but instead of the HRP enzyme, the detector antibody is conjugated with biotin, and then the fluorescence value is measured by treating it with a fluorescent substance conjugated to streptavidin. The antigen or detection target substance is first reacted and attached to the capture antibody, and then the detection antibody conjugated with biotin is treated so that the detection antibody attaches to the antigen or detection target substance on the other side than the place where the capture antibody is attached to the antigen or detection target substance. After that, the fluorescent substance e-flour conjugated to streptavidin is treated to measure the fluorescence signal of each magnetic particle. The higher the concentration of the diagnostic marker in the sample, the stronger the fluorescence signal of the magnetic particles. Based on this principle, the location of the magnetic particles in the reaction well is confirmed using a bright field microscope, and the fluorescence signal corresponding to that location is measured in pixel units. The fluorescence signals from about 10 magnetic particles are automatically image analyzed. The fluorescence values from the test detection are applied to a standard curve, which is graphed using the fluorescence values obtained by reacting the target substance to be detected at different concentrations in the same manner, to calculate the detection concentration value of the corresponding target protein in the final sample. All image analysis and calculation of fluorescence values are performed using an automatic image analysis program installed in the analysis device.
[0121] The above immunodiagnostic method can be performed using the POCT method. In the present invention, POCT stands for point-of-care testing, which means performing the test directly at the patient's location. In other words, it means that clinical pathology tests are performed by doctors, nurses, or clinical pathologists in the vicinity of the patient, such as in a ward, emergency room, operating room, or intensive care unit, rather than in an independent space such as a hospital's central laboratory. In the case of conventional traumatic brain injury diagnosis, large equipment such as CT or MRI was required, making on-site testing impossible. In the case of immunodiagnostic diagnosis, large diagnostic equipment such as automated CLIA devices was also required, so its use was limited to on-site diagnosis. However, in the case of the present invention, since miniaturized diagnostic equipment can be used, diagnosis at the scene can be performed using the POCT method.
[0122]
[0123] As described above, in the case of the present invention, at least one of the cartridge for automatic antibody coupling and the cartridge for post-antibody coupling confirmation is used selectively or sequentially, so that antibody coupling and post-coupling confirmation can be performed as a single process.
[0124] The magnetic rod is installed at the top of the well of the cartridge, and can be installed to move up and down so as to enter the inside of the well. As described above, the magnetic particles of the present invention can be manufactured to have paramagnetism. Therefore, when the magnetic rod enters the inside of the well, it is coupled to the magnetic rod, and when the magnetic force of the magnetic rod disappears, it can be separated from the magnetic rod and float inside the well. By applying this, when the magnetism of the magnetic rod is intermittently applied, the magnetic particles can be mixed inside the well, and also, when the magnetism of the magnetic rod is removed and the magnetic rod is moved up and down, the fluids inside the well can be physically mixed. In addition, it is also possible to apply the magnetism of the magnetic rod inside a well having magnetic particles and then move it to an adjacent well, thereby selectively moving the magnetic particles inside the well to the next well.
[0125] That is, the coupling process of the magnetic particles and the confirmation process of the coupled magnetic particles can be performed by moving the magnetic rod vertically and horizontally.
[0126] Looking at the structure of the above magnetic rod in detail, it is preferable that the magnetic rod has a diameter that can enter the cartridge, and a shape that corresponds to the inner surface of the well formed in the cartridge. That is, when the well is formed in a cylindrical shape, the magnetic rod may be formed in a cylindrical shape with a smaller diameter than the inner surface of the well, and even when the well is formed in a square column shape, the magnetic rod may have a square column shape with a small cross-sectional area. However, when the cross-section of the well is not circular, the magnetic rod may have a cylindrical shape that can enter the well.
[0127] In addition, the magnetic bar may be a paramagnetic material having one end that enters the well and the other end to which a magnetic substance is bound. As described above, the magnetic bar may also be used to mix the well. In this case, it is preferable that the magnetic bar be used after its magnetism has been removed. To this end, rather than the magnetic bar itself having a magnetic force, the magnetic force of the magnetic suit can be applied or removed by binding and detaching a magnetic substance to and from the other end of the magnetic bar. In this case, the magnetic substance may be a permanent magnet or an electromagnet, and an electromagnet is preferably used.
[0128] The device may further include a tip cover that surrounds the lower portion of the magnetic rod and moves up and down simultaneously with or separately from the magnetic rod. The tip cover may move simultaneously with the magnetic rod, or may move separately from the magnetic rod. The tip cover can prevent the used magnetic rod from making direct contact with the inside of the well, and thus, even when replacing the cartridge, it is possible to continue the experiment by replacing only the tip cover.
[0129] It may include an image acquisition unit capable of photographing the inside of one or more of the above wells. As described above, at the end of the confirmation cartridge after antibody coupling, there are magnetic particles combined with fluorescent particles, and the image acquisition unit can perform confirmation (QC) of the magnetic particles using the fluorescent image. In addition, when the cartridge includes an immunodiagnostic cartridge as described above, a fluorescent image can be acquired using the image acquisition device as described above, and immunodiagnosis can be performed based on the fluorescent image.
[0130] This image acquisition device may include a light source, CCD, and lens, similar to existing image acquisition devices. However, since installing the existing image acquisition device as is would require a large amount of space, in the case of the present invention, the components of the light source, CCD, and lens can be separated and then installed within the automatic antibody coupling and the device for confirming the same of the present invention.
[0131]
[0132] Hereinafter, preferred embodiments of the present invention will be described with reference to the accompanying drawings so that those skilled in the art can easily implement them. Furthermore, when describing the present invention, detailed descriptions of related, known functions or configurations will be omitted if they are deemed to unnecessarily obscure the gist of the present invention. Furthermore, certain features presented in the drawings may be enlarged, reduced, or simplified for ease of explanation, and the drawings and their components are not necessarily drawn to scale. However, those skilled in the art will readily understand these details.
[0133]
[0134] Preparation example
[0135] The process of autoantibody coupling and its confirmation was performed using the devices shown in Figures 1 and 2.
[0136] At this time, the composition of each cartridge is as follows.
[0137] Cartridge for autoantibody coupling
[0138] Well 1: Magnetic particles in MES buffer
[0139] Well 2: EDC / NHS solution in MES buffer
[0140] Well 3: Capture antibody solution in HEPES buffer
[0141] Well 4: Blocking buffer
[0142] Well 5: HEPES buffer
[0143] Well 6: Washing buffer
[0144] Well 7: Washing buffer
[0145] Well 8: Blocking buffer
[0146] Cartridge for confirmation after antibody coupling
[0147] Well 1: Magnetic particles in Blocking buffer
[0148] Well 2: 2nd Ab solution in Blocking buffer
[0149] Well 3: SA-PE solution in Blocking buffer
[0150] Well 4: Not in use
[0151] Well 5: Washing buffer
[0152] Well 6: Washing buffer
[0153] Well 7: Washing buffer
[0154] Well 8: PBS buffer
[0155] (SA-PE is Phycoerythrin with streptavidin attached)
[0156]
[0157] Example 1
[0158] Autoantibody coupling was performed on approximately 2,500 magnetic particles with a length of 300 μm using the device shown in Figs. 1 and 2.
[0159] The antibody coupling cartridge configuration is as in the above preparation example and Figure 8. The antibody (capture antibody) used at this time was GFAP antibody (Anit-GFAP).
[0160] Each coupling was repeated three times, and the intensity of fluorescence was measured for each. In addition, QC was performed three times for each sample using a confirmation cartridge after antibody coupling, and the intensity of fluorescence was measured. The QC cartridge configuration used at this time is as shown in the preparation example above and FIG. 10.
[0161] 1st 2nd 3rd 1st QCMFI36777.8437793.4737390.642nd QCMFI39412.0638988.3238370.903rd QCMFI37406.3540211.3437792.90AVE37865.4238997.7137851.48STD1123.34987.11402.33CV(%)2.972.531.06
[0162] As shown in Table 1, the auto-antibody coupling of the present invention and the device for confirming the same exhibited very low dispersion (less than 3%), indicating excellent reproducibility. This means that the auto-antibody coupling of the present invention and the device for confirming the same can achieve high accuracy.
[0163]
[0164] Example 2
[0165] We compared the existing manual (human-based) method with the automated antibody coupling method of the present invention. The conditions used in each method are as follows.
[0166] Autoantibody coupling
[0167] Automatic antibody coupling was performed using approximately 2,500 magnetic particles with a length of 300 μm using the device shown in Figs. 1 and 2.
[0168] The antibody coupling cartridge configuration is as in the above preparation example and Figure 8. The antibody (capture antibody) used at this time is GFAP antibody (Anit-GFAP).
[0169] After antibody coupling, each sample was QC-tested three times using the confirmation cartridge (Fig. 10).
[0170]
[0171] Manual antibody coupling
[0172] Researchers manually coupled approximately 2,500 magnetic particles, each 300 μm in length, using conventional methods. Two different researchers performed the couplings.
[0173] For reagents and antibodies used, the same as for autoantibody coupling.
[0174] After antibody coupling, verification (QC) is also done manually, as with the conventional method.
[0175] Autoantibody coupling manual coupling #1 manual coupling #21st QCMFI36777.8429821.2726468.452nd QCMFI39412.0633512.8133548.443rd QCMFI37406.3530139.7434155.61AVE37865.4231157.9432057.47STD1123.341670.212549.93CV(%)2.975.367.95
[0176] As shown in Table 2, the auto-antibody coupling of the present invention had a dispersion of less than 3%, confirming excellent reproducibility. However, when coupling was performed manually, the dispersion was high, and the dispersions of different researchers were different, confirming that the skill of the researcher is very important.
[0177] In addition, when coupling and QC were performed using the automatic antibody coupling of the present invention and the device for confirming the same, the average time required was measured to be 1 hour and 46 minutes, and when coupling and QC were performed manually, an average of 4 hours and 23 minutes were required. Therefore, it was confirmed that coupling with uniform accuracy was possible in a shorter period of time using the automatic antibody coupling of the present invention and the device for confirming the same compared to existing methods.
[0178]
[0179] Example 3
[0180] Immunodiagnosis was performed using the same autoantibody coupling and device for confirming the same as those used in Examples 1 and 2 above.
[0181] The configuration of the cartridge used at this time (Fig. 11) is as follows.
[0182] cartridge for immunodiagnostic testing
[0183] Well 1: Magnetic particles in MES buffer
[0184] Well 2: Antigen in Assay buffer
[0185] Well 3: Washing buffer
[0186] Well 4: Detection Antibody in Assay buffer
[0187] Well 5: SA-PE in Blocking buffer
[0188] Well 6: Washing buffer
[0189] Well 7: Washing buffer
[0190] Well 7: PBS buffer
[0191]
[0192] In the above Example 1, the autoantibody-coupled magnetic particles were used.
[0193] The antibody used is Anit-GFAP, and GFAP is used as the antigen.
[0194] The configuration of the cartridge used is the same as in Fig. 12.
[0195] Repeated over 3 stages
[0196] Antigen concentration (pg / ml) 1st 2nd 3rd AVG.STDCV (%) 200 267 16 252 202 53 93 25 7 76.33 66 8.192.59 100 146 4 11 5 4 30 145 8 2 1 4 8 8 4.33 38 6.60 2.60 50 95 4 9 8 7 19 5 5 3 9 6 5 6.00 15 2.07 1.57 25 5 7 5 3 5 5 4 15 4 25 5573.00135.802.4412.54910486551414972.00120.902.436.253868366036463724.67101.512.733.1253086309132073128.0055.901.7901158113412071166.3330.382.60
[0197] As shown in Table 3, it was confirmed that immunodiagnosis could be performed using the magnetic particles manufactured in Example 1 of the present invention. In addition, it was confirmed that the immunodiagnosis also had high reproducibility, as the deviation (CV) was small in each immunodiagnosis.
[0198] In addition, in the case of the present invention, it was confirmed that an antigen concentration of 3.125 pg / ml can be clearly distinguished from an antigen concentration of 0 pg / ml, and it was confirmed that the detection limit of the present invention is at least 3.125 pg / ml.
[0199]
[0200] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A cartridge containing a plurality of wells; A magnetic rod installed on the upper part of the well of the cartridge and moving up and down to enter the well; and An image acquisition unit capable of photographing the interior of one or more of the above wells; Includes, The above cartridge is selectively used as one or more of a cartridge for automatic antibody coupling and a cartridge for confirmation after antibody coupling. An automatic antibody coupling device and a device for confirming the same, wherein one or more wells of the cartridge are loaded with magnetic particles.
2. In paragraph 1, The above magnetic particles are A core comprising a magnetically responsive metal; a shell layer having a uniform thickness surrounding the core; and A capture probe is introduced onto the shell layer to capture a biological material, An automatic antibody coupling and a device for confirming the same, wherein the magnetic particles are cut pieces of glass-coated metal microwires.
3. In paragraph 1, The automatic antibody coupling and the device for confirming the same are characterized in that the automatic antibody coupling and the device for confirming the same further include a tip cover that surrounds the lower part of the magnetic bar and moves up and down simultaneously with or separately from the magnetic bar.
4. In paragraph 1, The above autoantibody coupling cartridge is, A first well loaded with the above magnetic particles; Second well loaded with EDC and NHS; The third well loaded with capture antibody; A fourth well containing a blocking buffer; and The fifth well containing the wash buffer; An autoantibody coupling comprising: and a device for confirming the same.
5. In paragraph 4, An autoantibody coupling and a device for confirming the same, characterized in that the first well and the second well additionally contain a 2-[N-morpholino]ethanesulfonic acid (MES) buffer.
6. In paragraph 4, A buffer buffer well is additionally included between the fourth and fifth wells. An automatic antibody coupling and a device for confirming the same, characterized in that the third well and the buffer buffer well contain a 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES) buffer.
7. In paragraph 1, The above-mentioned antibody coupling confirmation cartridge is, A first well loaded with magnetic particles coupled with capture antibodies; A second well loaded with the second agent; A third well loaded with fluorescent particles; and The fourth well containing the wash buffer; An autoantibody coupling comprising: and a device for confirming the same.
8. In paragraph 7, An automatic antibody coupling and a device for confirming the same, characterized in that the second antibody is bound to the capture antibody through an antigen-antibody reaction, and the fluorescent particle is bound to the second antibody.
9. In paragraph 7, An automatic antibody coupling device and a device for confirming the same, wherein the first to third wells further include a blocking buffer.
10. In paragraph 1, An automatic antibody coupling and a device for confirming the same, characterized in that the above cartridge additionally includes an immune diagnostic cartridge.
11. In paragraph 10, The above-mentioned immune diagnostic cartridge is, A first well loaded with magnetic particles coupled with capture antibodies; A second well loaded with antigen; The third well loaded with detection antibody; A fourth well loaded with fluorescent particles; and The fifth well containing the wash buffer; An autoantibody coupling comprising: and a device for confirming the same.
12. In paragraph 11, An automatic antibody coupling and a device for confirming the same, characterized in that the magnetic particles coupled with the above-mentioned capture antibodies are a mixture of two or more magnetic particles having different lengths, and the magnetic particles having different lengths contain different capture antibodies.
13. In paragraph 1, The above automatic antibody coupling and the device for confirming the same are characterized in that the magnetic rod moves up and down and horizontally to perform the coupling process of the magnetic particles and the confirmation process of the coupled magnetic particles.
Citation Information
Patent Citations
Flow-through assay with an internal calibration systemusing magnetic particles
KR101032172B1
Apparatus and method for diagnosis by magnetic nanoparticle
KR101515127B1
Highly sensitive in vitro diagnostic kit and diagnostic analysis method using the same
KR101994411B1
Temporary base such as lids for kitchen pots, etc.
KR102431168B1
